Cepheid
Cepheid is a global leader in molecular diagnostics, dedicated to improving healthcare by developing, manufacturing, and marketing automated, easy-to-use molecular systems and tests. Their mission is to provide rapid, accurate, and actionable genetic testing for a wide range of infectious diseases, oncology, and human genetics. Cepheid's flagship GeneXpert System delivers scalable, sample-to-answer PCR testing for institutions of any size, supporting both centralized and decentralized care. The company is committed to expanding access to high-quality diagnostics worldwide, supporting public health initiatives, driving innovation in molecular testing, and advancing sustainability and responsible business practices.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Thermal control device and methods utilizing temperature distribution modeling
2025-06-03 • US-12321183-B2
View Details
Thermal control device and methods utilizing temperature distribution modeling
2025-06-03 • US-12321183-B2
View DetailsProducts
Automated PCR-based diagnostic system
Instrument platform for automated molecular amplification and detection that supports scalable configurations for both core laboratory and near-patient environments and operates with modular assay formats.
Modular molecular assay cartridges for infectious diseases
Cartridge-format molecular assays targeting multiple infectious disease indications to enable pathogen detection and differentiation at the point of care or in laboratories.
Automated PCR-based diagnostic system
Instrument platform for automated molecular amplification and detection that supports scalable configurations for both core laboratory and near-patient environments and operates with modular assay formats.
Modular molecular assay cartridges for infectious diseases
Cartridge-format molecular assays targeting multiple infectious disease indications to enable pathogen detection and differentiation at the point of care or in laboratories.
Expertise Areas
- Point-of-care and near-patient molecular diagnostics
- Molecular infectious-disease testing (tuberculosis, hepatitis C, respiratory pathogens)
- Deployment of diagnostics in low-resource and public-health settings
- Clinical workflow integration and health IT connectivity
Key Technologies
- Automated PCR-based molecular diagnostics
- Point-of-care/near-patient testing platforms
- Cartridge-format multiplex molecular assays
- Clinical workflow connectivity and laboratory informatics
Key People
President
Vice President, Value and Access
Senior Vice President, Research & Development
Senior Vice President, Regulatory and Clinical Affairs
Senior Vice President, Global Commercial Operations
Vice President, Global Danaher Business System Leader
President
Vice President, Value and Access
Senior Vice President, Research & Development
Senior Vice President, Regulatory and Clinical Affairs
Senior Vice President, Global Commercial Operations
Vice President, Global Danaher Business System Leader
News & Updates
Cepheid's Xpert MTB/RIF test received World Health Organization endorsement as a major milestone for TB and MDR-TB care delivery.
Cepheid rapidly developed and received FDA Emergency Use Authorization for its Xpert Xpress SARS-CoV-2 test during the COVID-19 pandemic.
Cepheid launched the first molecular test to detect HCV RNA levels directly from a fingerstick of blood.
Article discussing the trade-offs between rapid antigen tests and PCR, highlighting the risk of missed diagnoses with antigen testing.
Review of the strengths of PCR-based molecular testing compared to antigen testing and the benefits of point-of-care molecular diagnostics.
Article on the importance of accurate diagnostics for vaginitis, including bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis.
Cepheid's Xpert MTB/RIF test received World Health Organization endorsement as a major milestone for TB and MDR-TB care delivery.
Cepheid rapidly developed and received FDA Emergency Use Authorization for its Xpert Xpress SARS-CoV-2 test during the COVID-19 pandemic.
Cepheid launched the first molecular test to detect HCV RNA levels directly from a fingerstick of blood.
Article discussing the trade-offs between rapid antigen tests and PCR, highlighting the risk of missed diagnoses with antigen testing.
Review of the strengths of PCR-based molecular testing compared to antigen testing and the benefits of point-of-care molecular diagnostics.
Article on the importance of accurate diagnostics for vaginitis, including bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis.